Clinical trials: Immune Responses
IgG4 Related Disease
Adaptive and Trained Immunity in the Pathogenesis of IgG4-Related Disease
Enquire involvement of trained immunity in the pathogenesis of IgG4RD
- Trial name
- TRIM4 (NCT06844864)
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Influenza
ADITEC FLU 2 STUDY: Understanding the Genetics Basis for Immune Responses to Flu Vaccines in Children and Adults
Influenza infection is related to significant morbidity and mortality in children. The trivalent inactive vaccine (TIV) has been documented to have poor immunogenicity in children and the live attenuated influenza vaccine (ATIV)…
- Trial name
- NCT02529904
- Testing
- MF59 - ATIV
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Oxford
B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission
Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methotrexate
This laboratory study is looking at response or resistance to chemotherapy in young patients with acute lymphoblastic leukemia treated with methotrexate.
- Conditions
- B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT00898404
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Children's Oncology Group
Yogurt Intake, Gastrointestinal Immune Function
Yogurt and GI Health
The purpose of this research is to assess mucosal immune function responses in the gastrointestinal (GI) tract to twice-daily yogurt consumption.
- Conditions
- Yogurt Intake, Gastrointestinal Immune Function, Gut Microbiome, Gut Health
- Trial name
- NCT05931471
- Testing
- Yogurt Intervention
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- USDA, Western Human Nutrition Research Center
Cholera, Diarrhea
Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine
The purpose of this study is to compare the safety and immunogenicity of one and two doses of the killed oral cholera vaccine.
- Conditions
- Cholera, Diarrhea, Vibrio Infections
- Trial name
- NCT00419133
- Testing
- Killed bivalent whole cell oral cholera vaccine
- Where
- India
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Malaria
Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region
GSK Biologicals is developing in partnership with the Program for Appropriate Technology in Health (PATH) Malaria Vaccine Initiative a candidate malaria vaccine for the routine immunization of infants and children living in…
- Trial name
- NCT00197028
- Testing
- RTS,S/AS02D, TETRActHib™, Engerix-B®
- Where
- Mozambique
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Melanoma
Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy
Cancer cells make proteins called antigens that act as markers for the tumor cells. These antigens cannot cause the cancer itself. Special white blood cells, called T cells or T lymphocytes, recognize and respond to antigens.
- Trial name
- NCT00700167
- Testing
- dendritic cell vaccine
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Mechanisms of Anti COVID-19 Humoral and Cellular Immune Response After Vaccination in a Sample of Patients and Salaried Staff From a French Anti-cancer Center
Special populations are people with a risk to dévelop severe forms of a disease. The immunogenicity and efficacy of vaccines in this population may be different compared of the general population.
- Trial name
- CANSEROVAX (NCT04935528)
- Testing
- serology and ELISPOT test, serology
- Where
- France
- Volunteers
- 539 people, healthy volunteers welcome
- Sponsor
- Centre Georges Francois Leclerc
Hodgkin Disease, Non-Hodgkin Lymphoma
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
This study investigates whether the prophylactic use of moxifloxacin during high-dose chemotherapy followed by autologous stem cell transplantation reduces the incidence of clinically significant bacteremia.
- Conditions
- Hodgkin Disease, Non-Hodgkin Lymphoma, Multiple Myeloma, Bacteremia
- Trial name
- MoxiProph (NCT00398411)
- Testing
- moxifloxacin
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- University of Cologne
Healthy
Training Study to Characterize Biomarkers to Flu Vaccines
It is thought that vaccines trigger innate inflammatory responses to induce antigen-specific adaptive immunity (the desired effect), but excessive inflammation may lead to serious inflammatory complications or unwanted side…
- Trial name
- NCT01771367
- Testing
- Fluad, Agrippal
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Poorly Differentiated Malignant Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Grade 3
Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study
The study is designed as an open-label, prospective, single arm, multicenter study of everolimus in histologically confirmed, neuroendocrine carcinoma G3 /neuroendocrine tumor G3 after failure of first-line platin-based…
- Conditions
- Poorly Differentiated Malignant Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Grade 3, Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3, Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3
- Trial name
- EVINEC (NCT02113800)
- Testing
- Everolimus (Afinitor®)
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- AIO-Studien-gGmbH
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor
This study will evaluate the efficacy and safety of MabThera in patients with active rheumatoid arthritis who have had an inadequate response to one prior anti-TNF alpha inhibitor.
- Trial name
- NCT02079532
- Testing
- rituximab [MabThera]
- Where
- 69 sites in Germany
- Volunteers
- 302 people
- Sponsor
- Hoffmann-La Roche
Antibody Persistance After Booster Dose of Men C Vaccine
Understanding Immunity Persistence After Adolescent MenC Vaccination
The main purpose of this study is to evaluate the duration of immunity after a booster dose of a MenC-CRM vaccine given to adolescents between 13 and 15 years of age.
- Trial name
- NCT01459432
- Testing
- Venepuncture and blood sample collection.
- Where
- United Kingdom
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Feasibility Study, Vaccine Immune Response
How Gut Health Affects Immune Responses to the Oral Rotavirus Vaccine in Adults in Zambia
The Rotavirus SpatioTrasncriptomics (Rota-Omics) study is a multidisciplinary research project aimed at understanding why oral rotavirus vaccines perform less effectively in some low- and middle-income countries, including…
- Conditions
- Feasibility Study, Vaccine Immune Response, Rota Virus Gastroenteritis, Transcriptomics
- Trial name
- Rota-Omics (NCT07626606)
- Testing
- Rotarix®,
- Where
- Zambia
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Diphtheria, Tetanus
Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE
PRIMARY OBJECTIVES To describe in 11 to 13-year-old children previously vaccinated with either REVAXIS or DT Polio at 6 years of age the antibody persistence against diphtheria, tetanus, and poliovirus types 1, 2 and 3 To…
- Conditions
- Diphtheria, Tetanus, Poliomyelitis
- Trial name
- NCT01546909
- Testing
- Diphtheria, tetanus, polio and pertussis vaccination
- Where
- 45 sites in France
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rheumatoid Arthritis
A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs
The objective of this study was to verify the superiority of ASP015K alone or in combination with disease-modifying antirheumatic drugs (DMARDs) over placebo in terms of efficacy in participants with rheumatoid arthritis (RA) who…
- Trial name
- NCT02308163
- Testing
- Peficitinib, Etanercept
- Where
- 153 sites in Japan, South Korea and 1 more
- Volunteers
- 509 people
- Sponsor
- Astellas Pharma Inc
Multiple Myeloma
Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)
To evaluate toxicity profile and efficacy of a tandem autologous-nonmyeloablative transplant approach in newly diagnose myeloma patients younger than 65 years
- Trial name
- NCT00702247
- Testing
- Hematopoietic Stem Cell Transplantation
- Where
- Italy
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
Pancreatic Cancer
Predicting Pancreatic Fistula After Pancreatic Surgery Using Preoperative Immunity
The goal of this observational study is to develop and validate a preoperative immunological signature for predicting postoperative pancreatic fistula (POPF) in adult patients undergoing pancreatic surgery for pancreatic cancer.
- Trial name
- NCT07827911
- Testing
- blood sampling
- Where
- France
- Volunteers
- 310 people
- Sponsor
- Institut Paoli-Calmettes
Dermatomyositis
Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis
This study will evaluate the safety and effectiveness of the experimental drug h5G1.1-mAb in treating patients with dermatomyositis.
- Trial name
- NCT00005571
- Testing
- h5G1.1-mAb
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Innate Immunity
Effect of Anti-Inflammatory Agents on Biological Responses to Endotoxin Inhalation in Healthy Subjects
The main objective of this study is to characterize the biological responses elicited by endotoxin inhalation applied to healthy subjects, and to assess the effect of standard anti-inflammatory agents (i.e.
- Trial name
- NCT02252809
- Testing
- adalimumab, methylprednisolone
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Brugmann University Hospital